NCCN Guidelines for Patients® | Esophageal Cancer - page 55

55
NCCN Guidelines for Patients
®
: Esophageal Cancer
Version 1.2013
Part 5: Squamous cell carcinomas
Par t 1
Par t 2
Par t 3
Par t 4
Par t 5
Par t 6
Par t 7
Par t 8
Par t 9
Notes:
First-line regimens
Preferred
Docetaxel, cisplatin, and 5-FU
Docetaxel, carboplatin, and 5-FU
Docetaxel, oxaliplatin, and 5-FU
Epirubicin, cisplatin, and 5-FU
Epirubicin, oxaliplatin, and 5-FU
Epirubicin, cisplatin, and capecitabine
Epirubicin, oxaliplatin, and capecitabine
Fluoropyrimidine (5-FU or capecitabine) and cisplatin
Fluoropyrimidine (5-FU or capecitabine) and oxaliplatin
5-FU and irinotecan
Other
Paclitaxel with cisplatin or carboplatin
Docetaxel with cisplatin
Docetaxel and irinotecan
Fluoropyrimidine (5-FU or capecitabine)
Docetaxel
Paclitaxel
_____________________
_____________________
_____________________
_____________________
_____________________
_____________________
_____________________
_____________________
_____________________
_____________________
_____________________
_____________________
_____________________
_____________________
_____________________
_____________________
_____________________
_____________________
1...,45,46,47,48,49,50,51,52,53,54 56,57,58,59,60,61,62,63,64,65,...100
Powered by FlippingBook